The various membrane events occuring during the inflammatory reaction and leading to the formation of lipid-derived mediators (prostaglandins, leukotrienes and PAF-acether) always involve a membrane enzyme activation namely phospholipase A2. This activation leads to the cleavage of the phospholipids present in the membrane and permits the release of an unsaturated fatty acid from the 2 position - usually, arachidonic acid - and to the simultaneous formation of a lysophospholipid. If the phospholipase A2-target phospholipid is an ether phosphatidyl choline, the lyso derivative formed is lyso PAF, the precursor of PAF-acether (Platelet Activating Factor, 1-0- alkyl- 2 - acetyl - sn- glycero- 3 - phosphocholine) (Figure 1). In inflammatory cells, the signal induced by inflammatory stimuli is transduced by a succession of events leading to the phospholipase A2 stimulation, allowing consequently the release in the cell of either arachidonic acid, precursor of prostaglandins and leukotrienes, or lyso-PAF, precursor of PAF-acether. These products, once formed, leave the cell and are able to stimulate neighbouring cell membranes, inducing again phospholipase A2 stimulation through stimulus-coupling events. An oversimplified view of the inflammatory reaction can be presented as an event stimulating the membrane of inflammatory cells, event coupled to transducing systems allowing the formation of lipid-derived mediators. These mediators, being stimuli by themselves amplify the phenomenon, rendering the inflammatory reaction rather similar to a nuclear reaction where the pile is phospholipase A2, and the combustible, phospholipids, always renewed by powerful acylating systems. Would phospholipase A2 be alone, the reaction would be endless and could become harmful for the biological environment where it takes place. Consequently, there must be some naturally occuring biological systems capable of controlling such a reaction. The discovery of lipocortin, a natural endogenous phospholipase A2 inhibitor, has focused the attention on the central role of pnospholipase A2 in the inflammatory reaction. Indeed, this discovery has been linked to the knowledge of the biochemical and cellular mode of action of glucocorticosteroids, which inhibit phospholipase A2 activity through the induction of the synthesis of lipocortin (Figure 2).
KeywordsInositol Triphosphate Epidermal Growth Factor Receptor Kinase Murine Thymocyte Tyrosine Kinase Substrate Rabbit Neutrophil
Unable to display preview. Download preview PDF.
- 4.DiRosa M, Flower RJ, Hirata F, Parente L, Russo-Marie F. Lipocortins, nomenclature announcement. Prostaglandins 1984; 28: 441–4Google Scholar
- 6.Rothhut B, Russo-Marie F, Cousin M, Lando D. Renocortin: a phospholipase A2 inhibitory protein induced by anti-inflammatory steroids: pharmacological and biological properties, development of monoclonal antibodies. In Proceedings of the 9th IUPHAR Congress of Pharmacology, P Turner, W Paton, JF Mitchell (eds), The Macmillan Press ltd. London, 1984: 43–6Google Scholar
- 9.Blake-Pepinsky R, Sinclair LK, Browning JL et al. Purification and partial sequence analysis of a 37 KDa protein that inhibits phospholipase A2 activity from rat peritoneal exudates. J Biol Chem 1986; 261: 4246–9.Google Scholar
- 15.Kristensen T, Saris CJM, Hunter T, Hicks LJ, Noonan DJ, Glenney JR, Tack B. Primary structure of bovine calpactin I heavy chain (p36), a major cellular substrate for retroviral protein-tyrosine kinases: homology with the human phospholipase A2 inhibitor lipocortin. Biochemistry 1986; 25: 4497–503.PubMedCrossRefGoogle Scholar